ArticlePloS one2025
A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leaf mold extract agar facilitates recovery of soil bacterial diversity beyond Bacillus dominance.Applied microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucorales fungi cause life-threatening mucormycosis in patients with clinical risk factors, such as immunodeficiency. Moreover, they are resistant to several antifungal drugs, highlighting the urgent need for novel therapies. Traditional mammalian models are expensive and raise ethical concerns, thereby limiting their suitability for large-scale studies. We established a silkworm (Bombyx mori) infection model to investigate the pathogenicity of Mucorales and evaluated its relevance to human infection. Strains of Rhizopus arrhizus, Mucor circinelloides, and Cunninghamella bertholletiae induced fatal infections in the silkworm. Grocott-stained silkworm tissue sections revealed hyphal invasion patterns closely resembling those observed in human mucormycosis. In addition, experimental simulation of clinical risk factors (steroid use and iron overload) significantly reduced the median lethal dose (LD50). Treatment with the antifungal drug isavuconazonium prolonged the survival of R. arrhizus-infected silkworms, suggesting the potential use of this model for novel antifungal screening. LD50 estimation for four R. arrhizus strains revealed up to a 100-fold difference in pathogenicity to the silkworm among the tested strains, corresponding to variations in cell surface characteristics. Interestingly, the presence of high-molecular weight (50-100 kDa) cell surface proteins was associated with high pathogenicity among R. arrhizus strains. In conclusion, the silkworm is a viable, human-relevant alternative model to investigate Mucorales infections, with potential for large-scale antimucormycosis drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.